Fenofibrate/pitavastatin - Hanlim PharmaceuticalAlternative Names: Pitavastatin/fenofibrate
Latest Information Update: 06 Oct 2014
At a glance
- Originator Hanlim Pharmaceutical
- Class Antihyperlipidaemics; Benzophenones; Butyric acids; Carboxylic acids; Cyclopropanes; Fibric acid derivatives; Fluorobenzenes; Propionates; Quinolines; Small molecules
- Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 01 Sep 2014 Phase-I clinical trials in Undefined indication (In volunteers) in South Korea (PO)